Orca-Q
Mixed Phenotype Acute Leukemia
University of FloridaCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 73/ 100
Competitive context
71 Active assets in the Mixed Phenotype Acute Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Daunorubicin St. Jude Children's Research Hospital | Phase 4 | BB |
ETOPOSIDE Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 3 | BB |
DEXAMETHASONE St. Jude Children's Research Hospital | Phase 4 | BB |
METHOTREXATE Children's Oncology Group | Phase 4 | BB |
Cytosin-Arabinosid Children's Oncology Group | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Orca-Q is also rated in:
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
CCC
Indicative ·
48 / 100
View asset →Chronic Myeloid Leukemia in Lymphoid Blast Crisis (Diagnosis)Dormant
CCC
Indicative ·
48 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →